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Introduction
Natural products from algae have been widely explored, since 
the beginning of the civilization, for human use as food and 
as medical treatments, starting with the traditional knowledge 
of tribes and ethnic groups. Many chemicals and products 
from algae have economic importance and are broadly used. 
Algae are a source of fiber, minerals, antioxidants, vitamins, 
pigments, steroids, lectins, halogenated compounds, 
polyketides, polysaccharides, mycosporine-like amino acids, 
proteins, polyunsaturated fatty acids and other lipids; thus, 
they are largely consumed in many countries. Furthermore, 
isolated compounds, extracts and fractioned extracts have 
been reported to yield important biological activities, including 
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A B S T R A C T
The use of indigenous or remote popular knowledge to identify new drugs against diseases 
or infections is a well-known approach in medicine. The inhabitants of coastal regions 
are known to prepare algae extracts for the treatment of disorders and ailments such as 
wounds, fever and stomach aches, as for the prevention of arrhythmia. Recent trends 
in drug research from natural sources have indicated that marine algae are a promising 
source of novel biochemically active compounds, especially with antiprotozoal activity. 
Algae survive in a competitive environment and, therefore, developed defense strategies 
that have resulted in a significant level of chemical structural diversity in various metabolic 
pathways. The exploration of these organisms for pharmaceutical and medical purposes has 
provided important chemical candidates for the discovery of new agents against neglected 
tropical diseases, stimulating the use of sophisticated physical techniques. This current 
review describes the main substances biosynthesized by benthic marine algae with activity 
against Leishmania spp., Trypanosoma cruzi and Trypanosoma brucei; the causative agents of 
leishmaniasis, Chagas disease and African trypanosomiasis, respectively. Emphasis is given 
to secondary metabolites and crude extracts prepared from marine algae.
© 2014 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editora Ltda. All rights reserved.
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anti-inflammatory, leishmanicidal, decrease in triacylglyceride 
levels in the liver and serum, for the treatment of Leprosy, 
as well as for their trypanocidal, antioxidant, anticancer and 
microbicidal properties (Tanaka et al., 1975; Cardozo et al., 
2007; Stein et al., 2011). Therefore, many studies have been 
published, and many patents for chemicals extracted from 
marine algae have been registered for human health and 
nutrition. Due to the different uses and wide availability of 
these photosynthetic organisms, the interest has turned 
from wild harvest to farming and controlled cultivation. The 
compounds isolated from marine algae have sophisticated 
chemical structures, and some have shown great potential 
in the pharmaceutical and medical areas, including drugs for 
neglected tropical diseases (NTD).
Neglected tropical diseases
Neglected tropical diseases (NTD) have a higher prevalence 
in tropical and subtropical regions, and affect more than 1 
billion people worldwide (WHO, 2013a). The World Health 
Organization (WHO) developed a list of seventeen NTD (WHO, 
2010a), including the protozoan-borne diseases leishmaniasis, 
Chagas disease and human African trypanosomiasis (HAT), 
the main topics of this review. NTD affect the poorest people 
around the world and are often overlooked by drug developers 
or others instrumental for drug access, such as government 
officials, public health programs and the news media. Part of 
the problem lies in the fact that pharmaceutical companies 
cannot recover the cost of developing and producing 
treatments for these diseases (Yamey and Torreele, 2002; 
Trouiller et al., 2002; Werneck et al., 2011). Of the 1,556 new 
drugs approved between 1975 and 2004, only 21 (1.3%) were 
specifically developed for the treatment of NTD, even though 
these diseases account for 11.4% of the global disease burden 
(DNDi, 2013).
In this review we address studies of new drugs from 
marine algae against the three major kinetoplastid 
diseases, leishmaniasis, Chagas disease and HAT; which 
are caused by the protozoa Leishmania spp., Trypanosoma 
cruzi and Trypanosoma brucei (order Kinetoplastid, family 
Trypanosomatidae), respectively. No natural marine products 
or their derivatives have entered pre-clinical testing for these 
diseases, even though numerous marine products that exhibit 
leishmanicidal or trypanocidal activity have been reported 
previously. This work reviews the extracts, fractions and 
compounds isolated from marine algae, reported to possess 
activity against Leishmania spp., T. cruzi and T. brucei.
The antiprotozoal activity of extracts, fractions and 
compounds is described according to their IC50 values (the drug 
concentration resulting in 50% parasite growth inhibition) and 
the selectivity index (SI). The latter parameter indicates the 
ratio of the IC50 value obtained for mammalian cells divided 
by the IC50 against the discussed protozoa for cytotoxicity 
evaluation. The selectivity index ratio values the cytotoxic 
activity on mammals cells to antiprotozoal activity. To allow 
the activity of the compounds to be compared independently 
of their molecular weight, all literature values have been 
converted into micromolar concentrations (μM) if necessary.
Leishmaniasis
Leishmaniasis is caused by more than twenty species 
of Leishmania, and is transmitted to humans by the bite of 
infected female phlebotomine sandflies (Pinto et al., 2011). 
The disease presents a wide range of clinical symptoms, 
including manifestations of cutaneous, mucocutaneous or 
visceral leishmaniasis. In the Old World (Africa, Europe, 
Asia), cutaneous leishmaniasis (CL) is caused by Leishmania 
major, L. tropica, L. aethiopica, and some zymodemes from L. 
infantum. In the New World, mainly in Latin America, the 
etiologic species involved are Leishmania braziliensis, the most 
prevalent species, followed by L. amazonensis, L. guyanensis, 
and L. panamensis. However, other species such as Leishmania 
mexicana, L. pifanoi, L. venezuelensis, L. peruviana, L. shawi and 
L. lainsoni, which primarily appear in the Amazon region and 
Central America can also be associated with CL. Leishmania 
donovani, a viscerotropic species from the Old World, may result 
in CL during or after visceral leishmaniasis (VL) and is known 
as post-kala-azar dermal leishmaniasis. Mucocutaneous 
leishmaniasis (ML) affects the nasal and oral mucosa and is 
caused by L. braziliensis, L. panamensis, L. guyanensis and L. 
amazonensis in the New World or by L. major and L. infantum in 
the Old World (Goto and Lindoso, 2010; 2012). VL is caused by 
L. donovani in Asia and Africa and by L. infantum in southern 
Europe and South America, where it used to be known as 
L. chagasi (Balasegaram et al., 2012). Although CL tends to 
spontaneously resolve, ML causes severe facial disfigurement 
and VL is fatal if untreated, causing a global annual mortality 
estimated at 59,000 cases (Den Boer et al., 2011).
Leishmaniasis affects approximately 350 million people 
around the world. As many as 12 million people are believed 
to be currently infected, and roughly 1-2 million estimated new 
cases occur every year (WHO, 2013b). The HIV/AIDS pandemic 
has contributed to the increased number of leishmaniasis 
cases in endemic areas (Alvar et al., 2008). In Brazil, more than 
27,000 cases of CL were reported between 1988 and 2009 (MS, 
2011), and more than 70,000 cases of VL and four deaths were 
reported between 1980 and 2008 (Werneck, 2010). 
The current treatment for leishmaniasis is chemotherapy; 
however it poses limitations such as toxicity, difficult route 
of administration and lack of efficacy in endemic areas. The 
glycosomal targets for anti-trypanosomatid drug discovery 
have been reviewed recently (Barros-Alvarez et al., 2013). 
Despite the efforts to find new drugs against Leishmania 
spp., the treatment of leishmaniasis is still based on the 
use of pentavalent antimonials (sodium stibogluconate and 
meglumine antimoniate), developed more than 60 years ago 
and are known to have several notable side effects, including 
nausea, abdominal colic, diarrhea, skin rashes, hepatotoxicity 
and cardiotoxicity. Furthermore, resistance to antimonials 
has been a growing problem for approximately four decades 
(Sundar, 2001; Maltezou, 2010). In addition, pentavalent 
antimonials are associated with high death rate, especially in 
HIV co-infected patients. Among the chemotherapeutic agents 
used as second-line treatment for leishmaniasis, the polyene 
antibiotic amphotericin B and its liposomal formulation are 
used against VL, and were introduced for this indication 
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(Balasegaram et al., 2012). Although it is highly effective, 
even in antimony-unresponsive patients, amphotericin B has 
restrictions due to its renal toxicity and inconvenient slow 
intravenous administration (Bhandari et al., 2012). Liposomal 
amphotericin B is preferred over conventional amphotericin B 
because of its milder toxicity profile, but its use remains very 
limited as a result of its high cost (Dorlo et al., 2012). Only in 
South America, pentamidine, an aromatic diamine, has been 
used in the treatment of CL (Croft and Olliaro, 2011), but severe 
adverse effects, including diabetes mellitus, hypoglycemia, 
shock, myocarditis and renal toxicity, limit its use (WHO, 
2010b). Paromomycin is an aminoglycoside antibiotic with 
described leishmanicidal activity; however, this drug has been 
documented to have variable efficacy in different countries 
and is not commonly used or widely available outside of Africa 
and the Indian subcontinent (Van Griensven and Diro, 2012; 
Singh et al., 2012).
Miltefosine, registered in 2002, is the first, and remains 
the only, oral agent used for the treatment of all types of 
leishmaniasis (Sundar and Rai, 2002; Singh and Sivakumar, 
2004; Dorlo et al., 2012), even though gastrointestinal side-effects 
(anorexia, nausea, vomiting and diarrhea), hepatotoxicity and 
renal insufficiency have been reported (WHO, 2010b). Despite 
efforts to fight this disease for the past 10 years, and to allow 
the use of lipid formulations of amphotericin B, miltefosine and 
paromomycin for the treatment of leishmaniasis, chemotherapy 
in many endemic countries, including Brazil, is still based 
on pentavalent antimonials or conventional amphotericin 
B; despite their inherent toxicities and complex route of 
administration (WHO, 2010b).
Chagas disease 
Chagas disease, or American trypanosomiasis, is caused by the 
parasite T. cruzi, which is spead by the bite of triatomine insects, 
popularly known as kissing bugs (Triatoma, Panstrongylus and 
Rhodnius) (Shaw et al., 1969; Mendonça et al., 2009). People 
can also be infected by blood transfusions, organ donations 
and congenital transmission (WHO, 2013c). Oral transmission 
has recently been recognized as the cause of sporadic, small 
human outbreaks, mostly in the Amazon region (Shikanai-
Yasuda and Carvalho, 2012). Chagas disease is characterized 
by an acute phase followed by a chronic phase, which is further 
classified into indeterminate, cardiac or digestive forms, 
presenting different clinical manifestations (Prata, 2001). The 
WHO estimates that approximately 10 million individuals are 
currently infected with T. cruzi and are at risk for developing 
cardiac or gastrointestinal pathology, normally associated with 
chronic Chagas disease (Afonso et al., 2012; WHO, 2013c).
Since the late 1960s and early 1970s, two drugs have 
been used in the treatment of Chagas disease: nifurtimox 
(Lampit®) and benznidazole (Lafepe-Benznidazole, Laboratorio 
Farmacêutico do Estado de Pernambuco) (Ribeiro et al., 2009). 
The average cure rate among acute cases is 80%, but these 
treatments are less effective for chronic cases; less than 20% 
of chronic cases are cured (Coura and Borges-Pereira, 2012).
The low efficacy of these drugs, and their unwanted side 
effects, restrict their use  (Urbina and Docampo, 2003). In addition, 
different strains of T. cruzi exhibit different levels of susceptibility 
to benznidazole and nifurtimox (Filardi and Brener, 1987; Murta 
and Romanha, 1998), which may explain in part the observed 
differences in the effectiveness of the chemotherapy. In Brazil, 
nifurtimox was withdrawn from the market due to its side effects 
(Bezerra et al., 2012). Thus, benznidazole has become the only 
option for the treatment of Chagas disease, despite its side effects 
and limited effectiveness in chronic cases (Urbina and Docampo, 
2003).
African trypanosomiasis
Another NTD with great impact in Africa is human African 
trypanosomiasis (HAT) or sleeping sickness. HAT is caused by 
the protozoan T. brucei and is transmitted by insects of the genus 
Glossina, known as tsetse flies. Their parasites infect nearly 30,000 
people annually, according to official data based on reported 
cases (Simarro et al., 2011), and another 60 million are living in 
at-risk areas (MSF, 2008). The WHO reports that Trypanosoma 
brucei gambiense causes 98% of HAT cases (WHO, 2013d).
The clinical presentation of HAT consists of two recognized 
stages: the early hemo-lymphatic stage, or stage I; and the 
late encephalitic stage involving the central nervous system, 
or stage II. In stage I, the patient experiences episodes of fever 
lasting 1-7 days that occur with generalized lymphadenopathy 
along with other non-specific symptoms including malaise, 
headache, arthralgia, generalized weakness and weight loss. 
In stage II, the parasites penetrate the blood-brain barrier 
and proliferate in the central nervous system, causing an 
encephalitic reaction that leads to death if the infection is 
untreated or inadequately treated. Two sub-species of T. brucei 
are related to the development of HAT: Trypanosoma brucei. 
gambiense, which is endemic to Western and Central Africa 
and has a chronic course of infection; and Trypanosoma brucei 
rhodesiense, which is endemic to Eastern and Southern Africa 
and exhibits a more acute pattern of progression compared 
with T. b. gambiense. (Dumas and Girard, 1979; Kennedy, 2008; 
MacLean et al., 2012).
For the treatment of stage I HAT, pentamidine is used against 
T. b. gambiense, whereas suramin is preferred against T. b. 
rhodesiense. Side effects have been reported for both treatments. 
Pentamidine causes significant toxicity in at least half of the 
patients, with life-threatening hypoglycemia being the most 
serious. A range of side effects, including nausea, vomiting, 
fatigue and shock followed by renal toxicity and neurological 
complications such as headache and peripheral neuropathy, 
have been reported for suramin (Jacobs et al., 2011).
For stage II HAT, melarsoprol is active against both T. 
b. rhodesiense and T. b. gambiense, whereas eflornithine 
and nifurtimox are effective only against T. b. gambiense. 
Eflornithine has replaced melarsoprol for T. b. gambiense in 
many endemic countries, and its use is recommended in 
combination with nifurtimox (Iten et al., 1997; Brun et al., 
2011). Melarsoprol is highly toxic and may cause death. The 
side effects for eflornithine alone include seizures, fever, 
infections, neutropenia, hypertension and diarrhea; all leading 
to death. Diarrhea, infections, fever, skin rash or hypertension 
have been reported for nifurtimox-eflornithine combination 
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therapy. Thus, the toxicity of all currently available drugs to 
treat HAT, the inconvenience of parenteral administration, the 
lack of a guaranteed drug supply and the increasing incidence 
of treatment failure, make the development of new therapeutic 
agents against HAT urgent.
Natural products and the development of new 
drugs
The WHO recommends that the governments of countries with 
a high incidence of NTD embrace the strategy of combining 
traditional knowledge of biodiversity with scientific endeavors 
to develop new therapies for NTD treatment (WHO, 2003). 
This recommendation is based on the historical development 
of global medicine; at least 25% of the active compounds of 
synthetic drugs currently prescribed were first identified in 
plant sources (Halberstein, 2005). According to Newman and 
Cragg (2012), from 1981 to 2010, approximately 40% of the 1,355 
new drug entities (small molecules) could be classified as truly 
synthetic in origin. The close relationship between biodiversity 
and drugs is obvious for specific categories. For example, 
approximately 70% of the new anti-infective medications 
developed during this period of time were classified as 
naturally derived or inspired by nature. As of antiparasitics, 
14 drugs were approved between 1981 and 2010, including two 
natural products and five compounds derived from natural 
products (i.e., drugs with a semi-synthetic modification) 
(Newman and Cragg, 2012).
The advent of scuba techniques and their utilization 
by researchers of natural producs, approximately 60 years 
ago, led to the identification of several compounds from 
marine organisms. The search for natural compounds is 
driven by the exceptional richness of secondary metabolites 
(including terpenes, steroids, polyketides, peptides, alkaloids 
and porphyrins) produced by many marine organisms, 
which allow them to survive in a competitive environment; 
therefore, these should be explored as chemical prototypes 
for drug discovery. The exploration of these organisms for 
pharmaceutical purposes has revealed chemical scaffolds 
important for the discovery of new agents, through the use 
of sophisticated techniques and synthesis of new compounds 
with biomedical application (Cardozo et al., 2007). In fact, the 
marine environment has proven to be a rich source of potent 
compounds with a number of different relevant biological 
effects, including antitumor, anti-inflammatory, analgesic, 
immunomodulatory, anti-allergy, anti-viral and antiparasitic 
activities; these effects have been described in the last decade 
by multiple reviews Newman and Cragg, 2004; Tempone et al., 
2011; Blunt et al., 2013; Mayer et al., 2013). To date, seven drugs 
from marine sources have been registered by the United States 
(US) Food and Drug Administration (FDA), and currently there 
are ten molecules, originated or derived from marine sources, 
in some phase of clinical development for the treatment 
of cancer, analgesia, allergy and cognitive diseases (http://
marinepharmacology.midwestern.edu/).
Benthic marine algae can be divided into red algae (Phyllum 
Rhodophyta), brown algae (Phyllum Heterokontophyta, Class 
Phaeophyceae) and green algae (Phyllum Chlorophyta). They 
play important roles in the marine environment and are 
the basis of the food web, transferring several micro and 
macroelements to the upper levels (Hollnagel et al., 1996; 
Gressler et al., 2010; 2011). Therefore, these photosynthetic 
organisms take up CO2 and generate O2 in aquatic bodies. Algae 
are responsible for the reduction of NO3 to NH3 because they 
possess the enzymes nitrate reductase and nitrite reductase 
(Lopes et al., 2002), needed for ammonia to be incorporated 
into carbon skeletons to build amino acids and other nitrogen 
compounds. Therefore, algae are considered to be the most 
important aquatic bioremediator due to their ability to absorb 
metals and organic pollutants. Metals are then sequestered 
by glutathione and stored in vacuoles, and the organic 
compounds are metabolized to yield small molecules (Leitão 
et al., 2003; Mendes et al., 2012). These organisms represent a 
great diversity of species, and are of great importance in the 
food, pharmaceutical, cosmetic and biotechnology industries 
as the source of several compounds with economic impact 
(Cardozo et al., 2006; Guaratini et al., 2007). In addition, these 
species are exposed to a highly competitive environment and 
synthesize several secondary metabolites that may represent 
an important source of new bioactive compounds with diverse 
pharmacological activities; thus, they may contribute to the 
development of new medicines. Currently, the research on the 
chemical elucidation of algal products with pharmaceutical 
activity has increased, and is focused on secondary 
metabolism; the sophisticated structural diversity obtained 
as a result of combined reactions from the primary metabolic 
pathways. Via the use of molecular biology, secondary 
metabolism has been clarified, and a large quantity of novel 
bioactive metabolites can be generated by genetic engineering. 
The search for natural compounds with pharmaceutical 
activity indicated marine macroalgae as promising organisms 
to supply novel biochemically active compounds. It is worth 
mentioning that an online database of compounds, including 
secondary metabolites, from macroalgae (predominantly from 
red algae) is available (Davis and Vasanthi, 2011). Between 
2009 and 2011, 191 articles were published describing the 
characterization of compounds or their biological activities as 
antitumor, antioxidant, anti-HIV, anti-HPV, antibacterial and 
antiparasitic (e.g., against Plasmodium falciparum, Trichomonas 
vaginalis, Giardia lamblia and Entamoeba histolytica), from 
different species of algae throughout the world (Blunt et al., 
2011; 2012; 2013). Nevertheless only one article was found 
regarding their leishmanicidal activity (dos Santos et al., 2011), 
Algae drugs against NTD
Photosynthetic organisms have constituted the basis of 
traditional medicinal systems for thousands of years, from the 
first records dated approximately 2600 B.C. in Mesopotamia. 
Ancient Egyptian, Chinese and Indian documents show that 
medicine in these societies incorporated numerous plant-based 
remedies and preventives, and most of which are still being 
used today to treat ailments ranging from coughs and colds, to 
parasitic infections and inflammation. Today, approximately 
80% of the world’s population relies on traditional plant-based 
medicines for primary health care (Gurib-Fakim, 2006).
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Marine algae hold a great potential for drug discovery, 
emphasized by their use, since approximately 300 BC, in 
traditional medicine to treat parasitic diseases. Chondria sp., 
Sargassum vulgare and Ulva sp. from Cuba; Sargassum thunbergii 
from Japan; and Laurencia microcladia, Jania capillaceae, Dictyota 
caribaea and Sargassum fluttans from the Gulf of Mexico 
have been used for their anti-helminthic and antiprotozoal 
properties. The pharmacological potential of marine algae 
as sources of new treatments for parasitic disease is proven 
by the  kainic acid, an amino acid content isolated from the 
tropical species Digenea simplex (Rhodophyta, Ceramiales). 
This species has been known for its anti-helminthic and 
insecticidal properties in East Asian countries for more than 
1000 years (Nitta et al., 1958; Moo-Puc et al., 2008). Traditional 
Chinese Medicine holds valuable information regarding the 
use of Sargassum seaweed, recorded in ancient manuscripts 
and summarized in books as the Chhinese pharmacopoeia, 
Compedium of Materia Medica (Liu, 2012). Sargassum thunbergii, 
also known as Hede, is traditionally used as anti-helminthic 
(Kang, 1968). Based on ethnopharmacological knowledge, 
modern phytochemical studies have recently proved the 
trypanocidal and leishmanicidal activity of crude extracts 
of Sargassum natan and Sargassum oligocystum, respectively 
(Orhan, 2006; Fouladvand et al., 2011).
The traditional use of algae for antiparasitic treatment 
has gained the attention of several research groups around 
the world, and marine secondary metabolites are now being 
evaluated as drug leads for the treatment of neglected 
diseases, such as leishmaniasis, Chagas disease and HAT. 
Currently, there are numerous studies aiming to discover 
antiparasitic natural products from marine organisms. The 
random exploration of extracts and compounds derived from 
natural products to identify molecules with antileishmanial 
and/or trypanocidal activity, requires quantitative, fast, simple 
and reproducible bioassays, and conditions that reflect those 
encountered by the parasite in the host cell (Sereno et al., 
2007). Several biological assays involving the manipulation 
of Leishmania promastigotes and amastigotes (Berg et al., 
1994; Sereno and Lemesre, 1997), T. cruzi trypomastigote and 
amastigotes (Buckner et al., 1996; Romanha et al., 2010) and 
T. brucei bloodstream trypomastigote form (Sykes et al., 2012; 
Sykes and Avery, 2013) are available. Most of these methods 
allow the evaluation of leishmanicidal or trypanocidal activities 
a large number of candidate compounds (Canavaci et al., 2010; 
Bolhassani et al., 2011). To date, no marine natural products 
or any derivatives have entered pre-clinical assessment 
for trypanosomatid diseases, but numerous antiprotozoal 
therapeutic extracts or fractions, and a few compounds from 
several seaweed species have been studied for potential lead 
compound isolation, medicinal applications or for modification 
(Sabina et al., 2005; Freile-Pelegrin et al., 2008; Veiga-Santos 
et al., 2010; da Silva Machado et al., 2011; dos Santos et al., 
2011; Fouladvand et al., 2011; Vonthron-Sénécheau et al., 2011; 
Soares et al., 2012). The following works described below refer 
to the evaluation of extracts and/or fractions obtained from 
several species of marine algae and their potential for future 
research to isolate the main active compound that could be 
used as a lead compound in the development of new drugs 
against leishmaniasis, Chagas disease and HAT.
Seaweed crude extracts belonging to the phylums 
Chlorophyta (Caulerpa racemosa [IC50 = 37.5 μg/ml], Ulva fasciata 
[IC50 = 50 μg/ml], Caulerpa faridii [IC50 = 34 μg/ml], Codium 
flabellatum [IC50 = 34 μg/ml], Codium iyengarii [IC50 = 60.4 μg/
ml], Ulva reticulate [IC50 = 64.75 μg/ml] and Ulva rigida [IC50 = 
65.69 μg/ml]) and Rhodophyta (Laurencia pinnatifida [IC50 = 6.25 
μg/ml], Melanothamnus afaqhusainii [IC50= 32.6 μg/ml], Gracilaria 
corticata [IC50 = 38 μg/ml], Scinaia hatei [IC50= 14.1 μg/ml], Scinaia 
indica [IC50 = 59.6 μg/ml], Centroceras clavulatum [IC50 = 57.89 μg/
ml] and Botryocladia leptopoda [IC50 = 60.81 μg/ml]) have been 
documented to exhibit strong activity against the promastigote 
form of L. major in vitro (Sabina et al., 2005).
Orhan et al. (2006) evaluated the in vitro antiprotozoal activity 
of ethanolic extracts of several Turkish marine macroalgae 
(Dictyota dichotoma, Halopteris scoparia, Posidonia oceanica, Sc. 
furcellata, Sargassum natans and U. lactuca). Although none of the 
extracts were active against T. cruzi trypomastigotes, all of the 
crude extracts elicited a trypanocidal activity against T. brucei 
rhodesiense bloodstream form; moreover, the S. natans extract 
was the most active (IC50 = 7.4 μg/ml). Except for the marine 
algae H. scoparia, all of the extracts possessed leishmanicidal 
potential against axenic amastigote forms. Furthermore, U. 
lactuta and P. oceanica had the greatest leishmanicidal activity 
(IC50 = 5.9 and 8.0 μg/ml, respectively) (Orhan et al., 2006).
Süzgeç-Selçuk et al. (2011) showed that methanolic extracts 
of algae belonging to Chlorophyta (Caulerpa racemosa and 
Codium bursa), Phaeophyta (Cystoseira barbata and Cystoseira 
crinata) and Rhodophyta (Corallina granifera, Jania rubens, 
Ceramium rubrum, Gracilaria verrucosa, Dasya pedicellata and 
Gelidium crinale) were active against T. brucei rhodesiense 
bloodstream forms, against which D. pedicellata extract was the 
most potent (IC50=0.37 μg/ml). The same extract also impaired 
the survival of T. cruzi trypomastigotes (IC50= 62.02 μg/ml). All 
of the extracts showed leishmanicidal activity (IC50 values 
ranging from 16.76 to 69.98 μg/ml) (Süzgeç-Selçuk et al., 2011).
Freile-Pelegrin et al. (2008) analyzed the aqueous and organic 
extracts of 27 species of marine algae from the Gulf of Mexico 
and the Caribbean coast of the Yucatan Peninsula (Mexico). 
The organic extracts from Laurencia microcladia (Rhodophyta), 
Dictyota caribaea, Turbinaria turbinata and Lobophora variegata 
(Phaeophyceae) showed promising results against L. mexicana 
promastigotes in vitro (IC50 values ranging from 10.9 to 50 μg/
ml) (Freile-Pelegrin et al., 2008).
De Felício et al. (2010) reported that the n-hexane and 
dichloromethane fractions of Bostrychia tenella (Rhodophyta) 
from the Sao Paulo Coast, Brazil, showed activity against T. 
cruzi trypomastigotes and L. amazonensis promastigotes. In 
a trypanocidal assay, the n-hexane and dichloromethane 
fractions showed IC50 values of 16.8 and 19.1 μg/ml, 
respectively. For the leishmanicidal assay, the n-hexane 
(H02, H03) and dichloromethane (D01 and D02) sub-fractions 
(obtained by chromatographic methods) were active against L. 
amazonensis promastigotes, exhibiting IC50 values of 1.5, 2.7, 4.4 
and 4.3 μg/ml, respectively (de Felício et al., 2010).
A group of marine algae belonging to Rhodophyta, 
Chlorophyta and Phaeophyceae collected from the 
United Kingdom was evaluated for antiprotozoal activity 
(Allmendinger et al., 2010; Spavieri et al., 2010a,b). 
Allmendinger et al. (2010) screened 23 marine algae 
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(Rhodophyta) crude extracts (Boergeseniella fruticulosa, 
Calliblepharis jubata, Ceramium virgatum, Chylocladia verticillata, 
Claviclonium ovatum, Corallina officinalis, Cryptopleura ramosa, 
Cystoclonium purpureum, Dumontia incrassata, Furcellaria 
lumbricalis, Gelidium pulchellum, Gracilaria gracilis, Halopitys 
incurvus, Halurus equisetifolius, Jania rubens, Lomentaria 
articulata, Mastocarpus stellatus, Osmundea hybrida, Osmundea 
pinnatifi, Plocamium cartilagineum, Polyides rotundus, Porphyra 
leucosticta and Porphyra linearis). The extracts were evaluated 
for biological activity against T. brucei rhodesiense, T. cruzi 
trypomastigote and L. donovani axenic amastigotes. All the 
algal extracts showed activity against the T. brucei rhodesiense 
bloodstream form, with C. officinalis and C. virgatum being the 
most potent (IC50 values of 4.8 and 5.5 μg/ml, respectively). 
Except for P. leucosticta, the extracts from all the seaweeds 
elicit leishmanicidal activity with IC50 values ranging from 
16.5 to 85.6 μg/ml. None of the algal extracts inhibited the 
growth of T. cruzi (Allmendinger et al., 2010).
Spavieri et al. (2010a) screened the crude extracts of four 
green marine algae (Cladophora rupestris, Codium fragile ssp. 
tomentosoides, Ulva intestinalis and Ulva lactuca). The crude 
extracts showed antiprotozoal activity against T. brucei 
rhodesiense, and C. rupestris was the most potent, exhibiting 
an IC50 = 3.7 μg/ml; only C. rupestris and U. lactuta exhibited 
moderate trypanocidal activity against T. cruzi (IC50= 80.8 
and 34.9 μg/ml, respectively). All of the extracts showed 
leishmanicidal activity when essayed against the axenic 
amastigotes of L. donovani, with IC50 values ranging from 12 to 
20.2 μg/ml (Spavieri et al., 2010a).
Spavieri et al. (2010b) evaluated the crude extracts of 21 
algae (Phaeophyceae) against T. brucei rhodesiense, T. cruzi and 
L. donovani. All of the algae extracts showed significant activity 
against T. brucei rhodesiense, with Halidrys siliquosa and Bifurcaria 
bifurcata (Sargassaceae) being the most potent (IC50 = 1.2 and 
1.9 μg/ml, respectively). All the algal extracts also displayed 
leishmanicidal activity, with H. siliquosa and B. bifurcata again 
being the most active (IC50 = 6.4 and 8.6 μg/ ml, respectively) 
(Spavieri et al., 2010b).
Vonthron-Sénécheau et  al .  (2011)  screened the 
hydroalcoholic and ethyl acetate extracts of twenty species of 
seaweeds from three phyla (Rhodophyta, Heterokontophyta 
and Chlorophyta) of the coast of Normandy, France. The ethyl 
acetate extracts were more active than the hydroalcoholic 
extracts. The most active extract against L. donovani axenic 
amastigotes was the ethyl acetate extract of B. bifurcata, 
which had an IC50 = 3.9 μg/ ml and a SI of 1.6. Nevertheless, D. 
polypodioides (IC50 = 10.8 μg/ ml, SI 8) and D. carnosa (IC50 = 9.5 
μg/ ml, SI 19) had higher IC50 values than B. bifurcate, as they 
were more selective for the parasite than for mammalian cells. 
The extracts did not show activity against T. cruzi (Vonthron-
Sénécheau et al., 2011).
Bianco et al. (2013) evaluated the antiprotozoal activity 
of 27 algae species against L. braziliensis promastigotes and 
intracellular amastigotes and against T. cruzi epimastigotes/
intracellular amastigotes. Six of the 27 species assayed showed 
activity against these protozoa. Extracts from Anadyomene 
saldanhae, Caulerpa cupressoides, Canistrocarpus cervicornis, 
Dictyota sp., Ochtodes secundiramea and Padina sp. at 50 μg/ml 
showed promising results against L. braziliensis (87.9, 51.7, 
85.9, 93.3, 99.7 and 80.9% growth inhibition, respectively). 
Only Dictyota sp. was effective against T. cruzi (60.4% growth 
inhibition). Unexpectedly, B. triquetrum, C. sertularioides, C. 
cupressoides, D. delicatula, G. caudata, H. cenomyce, H. musciformis, 
P. papillosa and Sargassum sp. had no antiprotozoal activity. 
Additionally, A. saldanhae (SI of 12.3) and Padina sp. (SI of 7.5) 
were effective against L. brasiliensis amastigotes (IC50= 24 
and 40 μg/ml, respectively), and C. cervicornis, C. cupressoides, 
Dictyota sp. and O. secundiramea were strongly cytotoxic for 
bone marrow macrophages (Bianco et al., 2013).
Nara et al. (2005) explored the inhibition potential of 
extracts from brown, red and green marine algae against the 
recombinant T. cruzi dihydroorotate dehydrogenase (DHOD), 
an essential enzyme involved in pyrimidine biosynthesis. The 
extracts from two brown algae, Fucus evanescens and Pelvetia 
babingtonii, showed 59 and 58% decrease in the recombinant 
DHOD activity, respectively, at 50 μg/ml and caused 
impairment in intracellular amastigotes survival in an in vitro 
T. cruzi-HeLa cell infection model at 1 μg/ml. The data showed 
that F. evanescens and P. babingtonii possibly contain inhibitor(s) 
of T. cruzi DHOD activity against the protozoan infection and 
proliferation in mammalian cells (Nara et al., 2005).
Marine algae produce several secondary metabolites, 
including halogenated compounds (Cabrita et al., 2010), 
sulfated polysaccharides (Berteau and Mulloy, 2003), 
triterpenes (Manriquez et al., 2001), diterpenes (Pereira et al., 
2004), acetogenins (Kladi et al., 2008), polyphenols (Aravindan 
et al., 2013) and others (Blunt et al., 2013; Mayer et al., 2013). 
Notably, terpenes, acetogenins, polyphenols and alkaloids 
from algae may be related to the observed antiprotozoal 
activity because metabolites of these types isolated from 
terrestrial plants have been reported to show leishmanicidal 
and trypanocidal activity (Chan-Bacab et al., 2003; Izumi et 
al., 2012; Santos et al., 2012; dos Santos et al., 2013). Indeed, 
halogenated terpenoids and acetogenins from the genera 
Bifurcaria, Laurencia, Dictyota and Canestrocarpus have shown 
leishmanicidal and trypanocidal activity (dos Santos et al., 
2010; Veiga-Santos et al., 2010; da Silva Machado et al., 2011; 
dos Santos et al., 2011; Soares et al., 2012).
The brown algae Bifurcaria bifurcata (order Fucales, 
family Sargassaceae) is able to synthesize a great number 
of diterpenes (Ortalo-Magné et al., 2005). The ethyl acetate 
extract of B. bifurcata showed strong trypanocidal activity 
(IC50 = 0.53 μg/ml) against T. brucei rhodesiense and a moderate 
SI of 12.4 in LC6 cells. Bio-guided fractionation revealed 
that the isolated diterpene elaganolone,(6E,10E,14E)-16-
hydroxy-2,6,10,14-tetramethyl-hexadeca-2,6,10,14-tetraen-
4-one (1), presented mild trypanocidal activity against the 
bloodstream forms of T. brucei rhodesiense (IC50 = 45 μM and 
SI 4.0) compared with the ethyl acetate extract. These data 
suggest that the trypanocidal activity of the extract may be 
due to other minor compounds, or to the synergy of several 
compounds separated during the fractionation process (Galle 
et al., 2013).
The sesquiterpenes elatol, (2R,3S,6R)-2-bromo-8-chloro-
1,1,9-trimethyl-5-methylenespiro[5.5]undec-8-en-3-ol (2), 
obtusol, (2S,3R,6S)-2,8-dibromo-9-chloro-1,1,9-trimethyl-
5-methylenespiro[5.5]undecan-3-ol (3) and triquinane, 
silphiperfol-5-en-3-ol (4), obtained from the Brazilian red 
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algae Laurencia dendroidea, showed antiprotozoal activity 
but no cytotoxicity to mammalian cells. Elatol (2) is the 
major constituent of L. dendroidea and showed trypanocidal 
activity against the trypomastigotes (IC50 = 1.38 μM, 
SI 20) and amastigotes (IC50 = 1.01 μM, SI 27) of T. cruzi 
(Veiga-Santos et al., 2010). This compound also proved 
to have antileishmanial activity when tested against the 
promastigote (IC50 = 4 μM) and intracellular amastigote 
(IC50 = 0.45 μM) forms of L. amazonensis. A cytotoxicity 
assay showed that the action of the isolated compound 
is slightly specific for protozoa (SI of 3) (dos Santos et al., 
2010). Further investigation of the mechanism of action of 
elatol (2) in T. cruzi revealed that this molecule could be 
involved in mitochondrial depolarization and an increase 
in superoxide anion (O2•−) production. This free radical may 
affect cell structures, leading to parasite death (Desoti et 
al., 2012).
Obtusol (3) showed low activity against both the 
promastigote (IC50 = 14.9 μM) and intracellular amastigote (IC50 
= 9.4 μM) of L. amazonensis, but this compound had a higher 
selectivity for the parasite cells (SI 34.23) compared with the 
reference drug, potassium antimony (III) tartrate hydrate (SI 
2.67) (da Silva Machado et al., 2011).
Triquinane (4) was less active than elatol (2) and obtusol 
(3) against both promastigote and amastigote cells (IC50 = 195 
μM and 219 μM, respectively) and had an SI of 3 for both the 
promastigote and amastigote cells (da Silva Machado et al., 
2011).
dolabelladienetriol (5) make it a promising candidate for 
leishmaniasis chemotherapy, either in isolated cases or in 
cases associated with HIV-1 (Soares et al., 2012).
The diterpene compound secodolastane, (4R,9S,14S)-4D-
acetoxy-9E,14D-dihydroxydolast-1(15),7-diene (6), isolated 
from C. cervicornis, exhibited an IC50 = 5.5 μM, 54 μM and 18 
μM for the promastigote, axenic amastigote and intracellular 
amastigote forms of L. amazonensis, respectively. The SI 
showed that the isolated diterpene 6 was 93 times less toxic 
to macrophages than to the protozoan (dos Santos et al., 2011). 
Table 1 summarizes the in vitro activities of compounds 1, 2, 
3, 4, 5 and 6.
Algal fucoidans (general representation by 7 ) are 
extracted from marine brown algae (e.g., Fucales, Laminares, 
Chordariales, Dictyotales, Dictyosiphonales, Ectocarpales and 
Scytosiphonales) and appear to be absent from green and red 
algae and terrestrial plants. These sulfated polysaccharides 
(7) are composed of L-fucose mainly (Berteau and Mulloy, 
2003; Li et al., 2008). Fucoidans have been approved in 
Japan and Korea commercially for many years, and for the 
past decade, fucoidans isolated from different species of 
brown algae have been extensively studied with respect to 
several biological activities, including antiviral (Schaeffer 
and Krylov, 2000; Cooper et al., 2002; Thompson and 
Dragar, 2004; Hayashi et al., 2008; Hidari et al., 2008; Taoda 
et al., 2008; Makarenkova et al., 2010) and anti-bacterial 
activities (Juffrie et al., 2006; Lutay et al., 2011). In 2011, Kar 
et al. showed that fucoidan administered to BALB/c mice 
infected with antimony-susceptible or antimony-resistant 
L. donovani  strains showed inhibitory effects on the 
amastigotes of both strains and resulted in a pronounced 
decrease in parasite burden (200 mg/kg/day; thrice/
daily). They further demonstrated that fucoidan induced 
a protective host cytokine response and significantly 
increased the ROS and NO levels in infected macrophages, 
which may have inhibited parasite multiplication (Kar et 
al., 2011).
Conclusion and perspectives
Macroalgae play important roles in the marine environment. 
They are the main organisms responsible for nitrate assimilation, 
the most abundant form of nitrogen found in the marine 
environment. Additionally, algae are photosynthetic organisms, 
primarily responsible for production of O2, and simultaneous take 
up of CO2. Algae are at the bottom of the food chain, and this 
position means that the nutritional composition of macroalgae 
plays an essential role in the food chain. The biochemical 
Dictyota pfaffii and Canistrocarpus cervicornis, brown algae 
belonging to the order Dictyotales, family Dictyotaceae, have 
shown antileishmanial activity (Soares et al., 2012; dos Santos 
et al., 2011). Soares and coworkers showed that the diterpene, 
Dolabelladienetriol, 8,10,18-trihydroxy-2,6-dolabelladiene 
(5), obtained from D. pfaffii, exhibits leishmanicidal activity 
against intracellular amastigotes (IC50 = 44 μM) and anti-HIV-1 
activity. These data are outstanding because HIV-1 is known 
to exacerbate the Leishmania load in macrophage infection; 
therefore, the leishmanicidal and anti-HIV-1 activities of 
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L. amazonensis 4 - 0.45 Desoti et al., 2012
T. cruzi 1.38 - 1.01
Veiga-Santos et al., 
2010 
3 L. amazonensis 14.9 - 9.4
da Silva Machado, 
Pacienza-Lima et 
al., 2011
4 L. amazonensis 195 219
da Silva Machado, 
Pacienza-Lima et 
al., 2011
Dictyota pfaffii 5 L. amazonensis - - 44 Soares, et al., 2012
Canistrocarpus 
cervicornis
6 L. amazonensis 5.5 54 18
dos Santos et al., 
2011
Table 1
Leishmanicidal and trypanocidal activities of diterpenes (1, 5 and 6) and sesquiterpenes (2, 3 and 4) compounds in μM.
composition of macroalgae, including the levels of fatty acids, 
sterols, amino acids, sugars, minerals and vitamins, determine 
the food quality transferred to other trophic levels. The search 
for natural products in different environments, together with 
the traditional knowledge of tribes and ethnic groups, plays an 
invaluable role and clue in the current drug discovery process. 
The investigation of marine macroalgal chemical compounds 
has proven to be a promising area of pharmaceutical study, 
resulting in new drugs with leishmanicidal and trypanocidal 
activity. Although the study and use of algal compounds against 
NTDs are recent, many reports have already been published 
describing isolated compounds from several algae with strong 
antiprotozoal activity and low toxicity. Therefore, the discovery 
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of novel molecules with a high therapeutic potential from marine 
macroalgae is very welcome.
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